{"id":8695,"date":"2019-06-19T10:45:38","date_gmt":"2019-06-19T14:45:38","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=8695"},"modified":"2019-06-22T15:05:51","modified_gmt":"2019-06-22T19:05:51","slug":"ipo-boutique-comments-on-stoke-therapeutics-inc-stok","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/ipo-boutique-comments-on-stoke-therapeutics-inc-stok\/","title":{"rendered":"IPO Boutique comments on Stoke Therapeutics, Inc. (STOK)"},"content":{"rendered":"<p><!--more--><br \/>\nCompany: <strong>Stoke Therapeutics, Inc.<\/strong><br \/>\nSymbol: STOK<br \/>\nDescription: They are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression.<br \/>\nShares: 6.7 million<br \/>\nPrice Range: $14.00-$16.00<br \/>\nMarket Cap: $425m-$485m<br \/>\nTrade Date: Thursday, 6\/20<br \/>\nUnderwriter(s): JP Morgan, Cowen, Credit Suisse<br \/>\nCo-Manager(s): Canaccord Genuity<br \/>\nTerms Added: 6-7-19<\/p>\n<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2019\/06\/Screen-Shot-2019-06-17-at-10.55.59-AM.png\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-8696\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2019\/06\/Screen-Shot-2019-06-17-at-10.55.59-AM-300x139.png\" alt=\"\" width=\"300\" height=\"139\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2019\/06\/Screen-Shot-2019-06-17-at-10.55.59-AM-300x139.png 300w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2019\/06\/Screen-Shot-2019-06-17-at-10.55.59-AM.png 357w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1623526\/000119312519167576\/d675029ds1a.htm\"><strong>LINK TO PROSPECTUS<\/strong><\/a><\/p>\n<p><strong>6\/17\/19, 11:05am ET &#8212; Stoke Therapeutics, Inc. (STOK) &#8212;\u00a0<\/strong>Channel checks just completed, are currently revealing, according to underwriter guidance that the deal is <strong>oversubscribed<\/strong>.\u00a0The underwriter states that the books are\u00a0scheduled to<strong>\u00a0close Monday at 4pm<\/strong>\u00a0in anticipation for a Wednesday debut.\u00a0<span style=\"font-weight: 400;\">There is no mention of insider buying on the cover of the prospectus. This company has a license agreement with <\/span><b>Cold Spring Harbor Laboratory and the Univ of Southampton<\/b><span style=\"font-weight: 400;\">. Notable existing shareholders include <\/span><b>Apple Tree Partners<\/b><span style=\"font-weight: 400;\"> (65.3% Pre-IPO stake and <\/span><b>RTW Investments<\/b><span style=\"font-weight: 400;\"> (11.9% pre-IPO stake). The company is gaining buzz for its Targeted Augmentation of Nuclear Gene Output platform <\/span><b>(TANGO) <\/b><span style=\"font-weight: 400;\">in which they can <\/span><span style=\"font-weight: 400;\">deliver in a highly precise, durable and controlled manner disease-modifying therapies to a broad range of relevant tissues<\/span><span style=\"font-weight: 400;\">. <\/span><span style=\"font-weight: 400;\">They designed their lead product candidate, <\/span><span style=\"font-weight: 400;\">STK-001,<\/span><span style=\"font-weight: 400;\"> to treat Dravet syndrome, a severe and progressive genetic epilepsy. <\/span><span style=\"font-weight: 400;\">Their latest fundraising round was in October 2018 at $8.93. <strong>Sector dedicated sources are very intrigued with this company.<\/strong> Additionally, there is a strong underwriting lineup on this deal. <\/span>\u00a0It should be noted that there are a\u00a0large amount of biotech offerings\u00a0on the schedule this week (6) and next week (4). This and Personalis Inc (PSNL) are our two &#8220;favorite&#8221; biotech offerings this week. Please monitor for potential information.\u00a0<strong>Rating = 3.\u00a0<\/strong><\/p>\n<p><strong>6\/18\/19, 9:45am ET &#8212; Stoke Therapeutics, Inc. (STOK) &#8212;\u00a0<\/strong>Channel checks just completed, are currently revealing, according to underwriter guidance that the deal is <strong>multiple-times\u00a0<\/strong><strong>oversubscribed<\/strong>.\u00a0The underwriter is currently guiding pricing <strong>above the prevailing $14.00-$16.00 range. <\/strong>A biotech IPO has not priced \u00a0above range, <em>according to our records<\/em>, since\u00a0<strong>Allakos Inc (ALLK)\u00a0<\/strong>in July 2018 (opened +51%, currently +140% vs. issue px).\u00a0Due to the strength and demand for this IPO, we are\u00a0<strong>increasing the rating on this deal from a &#8216;3&#8217; to a &#8216;4&#8217;<\/strong><span style=\"font-weight: 400;\">\u00a0<\/span>Needless to say, this and Personalis Inc (PSNL) remain our two &#8220;favorite&#8221; biotech offerings this week.\u00a0<strong>Rating = 4.\u00a0<\/strong><\/p>\n<p><strong>Stoke Therapeutics (STOK) priced an upsized offering of 7.89mm shares \u00a0(originally 6.7mm) at $18.00 ($2.00 above range) and opened at $27.21 for a gain of 51.2% at first trade.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,1536],"tags":[],"class_list":["post-8695","post","type-post","status-publish","format-standard","hentry","category-ipo","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/8695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=8695"}],"version-history":[{"count":5,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/8695\/revisions"}],"predecessor-version":[{"id":8768,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/8695\/revisions\/8768"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=8695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=8695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=8695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}